FDA-approved pancreatic cancer drug daraxonrasib extends median survival by 6.5 months
EricTopol · x · 2026-09-15
Eric Topol highlights progress against pancreatic cancer: the recently FDA-approved drug daraxonrasib from Revolution Medicines extends median survival by 6.5 months. He calls it a positive step but not enough, pointing to a new Cancer Cell paper that lays out a path toward further gains.
More from Research
- Peking University Releases MobileVLA-R1 2.0 with RL-Enhanced Robot Control — PekingUniversity · 2026-09-15
- Researchers propose separate repository for AI-written, AI-verified papers as publishing norms buckle — ChenhaoTan · 2026-09-15
- Human Connectome Model Plays RUSH E: Brain Network Drives Lightsaber Rhythm Game — anselm · 2026-09-15
- Google's AI predicts effects of 9 billion possible human DNA changes — rand_longevity · 2026-09-15
- Full fruit fly brain map, 166,700 neurons, flies a drone in real time — anselm · 2026-09-15
- Eric Topol spotlights the case for a science of the AI mind — EricTopol · 2026-09-15